NCT03594123: A reported trial by Otsuka Pharmaceutical Development & Commercialization, Inc.
This trial has reported on time, in line with the regulations.
Full data
| Full entry on ClinicalTrials.gov | NCT03594123 |
|---|---|
| Title | A 12-week, Multicenter, Active-treatment Extension Trial to Evaluate the Safety and Tolerability of Brexpiprazole in the Treatment of Subjects With Agitation Associated With Dementia of the Alzheimer's Type |
| Results Status | Reported |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Oct. 11, 2018 |
| Completion date | Sept. 19, 2022 |
| Required reporting date | Sept. 19, 2023, midnight |
| Actual reporting date | Sept. 18, 2023 |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | None |